



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/824,200	04/03/2001	Douglas A. Russell	18337.006	5401

7590

05/20/2003

ARNOLD & PORTER

Attn: IP Docketing Department Room 1126B
555 - 12th Street NW
Washington, DC 20004-1206

EXAMINER

FREDMAN, JEFFREY NORMAN

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 05/20/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.

09/824,200

Applicant(s)

RUSSELL ET AL

Examiner

Jeffrey Fredman

Art Unit

1634

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 11 April 2003. FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) ☐ The period for reply expires _____ months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
- ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action, or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☐ A Notice of Appeal was filed on 11 April 2003. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☒ The proposed amendment(s) will not be entered because:
- (a) ☒ they raise new issues that would require further consideration and/or search (see NOTE below);
- (b) ☐ they raise the issue of new matter (see Note below);
- (c) ☒ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
- (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

3. ☐ Applicant's reply has overcome the following rejection(s): _____.
4. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☒ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☒ For purposes of Appeal, the proposed amendment(s) a) ☒ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:


Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 1-10, 13, 20, 22 and 91-93.

Claim(s) withdrawn from consideration: _____.

8. ☐ The proposed drawing correction filed on _____ is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. ☐ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.
10. ☐ Other: _____


Jeffrey Fredman
Primary Examiner
Art Unit: 1634

Continuation of 2. NOTE: The new claim would require further search and consideration to identify art relating to Maize plants. Therefore, the amendment will not be entered.

Continuation of 5. does NOT place the application in condition for allowance because:

Applicant argues that the calculation made in the rejection that 1000 ng IL-4 per gram of Calli does not show that there is inherently more than 1% of soluble protein in the cell. Applicant attempts to support this argument by relying on textbooks to show that only 10-20% of total cell weight is protein. This is not evidence with regard to the Calli of plants, but with regard to something else. Therefore, this argument is solely argument, without supporting evidence. As MPEP 716.01 c) notes "The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art". Thus, the argument that the prior art is inoperable must be supported by evidence, not argument.

Further, all of Applicant's arguments are in direct contradiction to the express statement of Lee, who teaches that the proteins can accumulate to 1.3% of leaf protein (see column 1, line 45). The citation of the Guo reference is inapposite since it involves a different protein under different conditions than those shown for IL-4. Further, the paper was published more than four years before the earliest filing date of the issued patent, so that the paper does not represent the identical method of the patent (or the patent could not have issued).

Applicant then argues that the molecular weight similarity as shown by the Western blot does not demonstrate that the IL-4 proteins are the same. In this case, the only evidence available, the blot, appears to show that they are the same. This evidence meets the burden on the office under MPEP 2112 to show evidence which tends to show inherency. The burden is now on Applicant to rebut this evidence. Any declaration with evidence, not simply argument, on this point would be considered, even at this late date.

Applicant then argues that there is no motivation to combine and no expectation of success with either of the secondary references. Specific motivation to combine is cited in the rejections, the first of which notes "An ordinary practitioner, taught by Lee a method which teaches 'high-level gene expression (abstract)' in plants would have been motivated to apply this high level gene expression method to express the G-CSF of Boone since Boone expressly suggests plant cell expression of the protein. Further an ordinary practitioner would have been motivated in order to get more protein, since Lee teaches high level expression."

In the second rejection, the issue of substituting a KDEL sequence onto the plant is based upon the expectation taught by Schouten that this would further improve yields. This is sufficient motivation to add this sequence.

Applicant then argues this is an "obvious to try" situation. The legal standard for "reasonable expectation of success" is provided by *caselaw* and is summarized in MPEP 2144.08, which notes "obviousness does not require absolute predictability, only a reasonable expectation of success, i.e., a reasonable expectation of obtaining similar properties. See, e.g., In re O'Farrell, 853 F.2d 894, 903, 7 USPQ2d 1673, 1681 (Fed. Cir. 1988)." In this factual case, there is express suggestion in the prior art of Lee that high level expression is functional. This sufficient for a reasonable expectation of success. The MPEP cites In re O'Farrell, which notes regarding "obvious to try" at page 1682, that,

"In some cases, what would have been 'obvious to try' would have been to vary all parameters or try each of numerous possible choices until one possibly arrived at a successful result, where the prior art gave either no indication of which parameters were critical or no direction as to which of many possible choices is likely to be successful. E.g., In re Geiger, 815 F.2d at 688, 2 USPQ2d at 1278; *Novo Industri A/S v. Travenol Laboratories, Inc.*, 677 F.2d 1202, 1208, 215 USPQ 412, 417 (7th Cir. 1982); In re Yates, 663 F.2d 1054, 1057, 211 USPQ 1149, 1151 (CCPA 1981); In re Antonie, 559 F.2d at 621, 195 USPQ at 8-9. In others, what was 'obvious to try' was to explore a new technology or general approach that seemed to be a promising field of experimentation, where the prior art gave only general guidance as to the particular form of the claimed invention or how to achieve it. In re Dow Chemical Co., 837 F.2d, 469, 473, 5 USPQ2d 1529, 1532 (Fed. Cir. 1985); *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1380, 231 USPQ 81, 90-91 (Fed. Cir. 1986), cert. denied, 107 S.Ct. 1606 (1987); In re Tomlinson, 363 F.2d 928, 931, 150 USPQ 623, 626 (CCPA 1966). The court in O'Farrell then, affirming the rejection, notes 'Neither of these situations applies here.' For the instant case, it is clear that neither situations applies here either. This is not a situation where the prior art suggests varying a variety of parameters, since the prior art directly points to the use of the vectors and plants of Lee. This is also not a situation where only general guidance was given. The prior art provides specific guidance directing the use of the plants of Lee for high level expression of cytokines, of which class GM-CSF is a member.